Status:
COMPLETED
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
Lead Sponsor:
The Retina Center of St. Louis County, PC
Conditions:
Exudative Macular Degeneration
Eligibility:
All Genders
50+ years
Brief Summary
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and ...
Detailed Description
Study parameters will include best corrected visual acuity, number of combination treatments, reduction of central foveal thickness by OCT measurement and development of exudative macular degeneration...
Eligibility Criteria
Inclusion
- \- MUST HAVE AGE RELATED MACULAR DEGENERATION
Exclusion
- \-
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT02287298
Start Date
August 1 2014
End Date
December 1 2015
Last Update
April 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Retina Center
St Louis, Missouri, United States, 63141